浙江醫藥(600216.SH):左氧氟沙星氯化鈉注射液獲得藥品註冊證書
格隆匯6月21日丨浙江醫藥(600216.SH)公佈,公司近日收到國家藥品監督管理局核准簽發的左氧氟沙星氯化鈉注射液100ml:0.5g的《藥品註冊證書》,本品按照化學藥品4類註冊批准,根據國家藥監局相關規定視為通過藥品質量和療效一致性評價。
左氧氟沙星屬於喹諾酮類抗生素,適用於敏感菌所致的呼吸系統感染、泌尿系統感染、生殖系統感染、皮膚軟組織感染、腸道感染、敗血症及其它感染。
截至目前,公司用於開展左氧氟沙星氯化鈉注射液項目已累計投入研發費用約400萬元。2020年公司乳酸左氧氟沙星製劑銷售收入7.4927億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.